Several clinicopathological parameters are considered to determine the risk of recurrence, such as lymph node involvement, tumor size, subtype and histological grade, lymphovascular invasion, proliferation markers, hormone-receptor (HR) status, and HER2/neu [5, 6]. The gene discussed is ERBB2; the disease is neoplasm.